13F Holdings
中文EN

SLS SELLAS Life Sciences Group, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1390478 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-37.8%
TTM EPS YoY28.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-40.3%
ROA-37.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6.6%
Debt / equity0.00x
Current ratio14.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$0$1.00M$7.60M
Cost of revenue$0$0$0$100,000$200,000
Gross profit——$0$900,000$7.40M
R&D expense$16.02M$19.10M$24.01M$20.27M$15.67M
SG&A expense$12.25M$12.42M$13.86M$12.58M$11.32M
Operating income-$28.27M-$31.51M-$37.87M-$41.95M-$25.29M
Pretax income-$26.86M-$30.88M-$37.34M-$41.30M-$20.94M
Income tax$0$0$0$0-$237,000
Net income-$26.86M-$30.88M-$37.34M-$41.30M-$20.70M
EPS (basic)-0.25-0.50-1.34-2.13-1.34
EPS (diluted)-0.25-0.50-1.34-2.13-1.34
Weighted avg. shares (diluted)109.05M61.20M27.78M19.40M15.48M
Banking
Net interest income——$525,000$317,000$6,000
Balance sheet
Cash & equivalents$71.79M$13.99M$2.63M$17.23M$21.45M
Receivables————$0
Current assets$75.21M$16.33M$3.17M$17.76M$23.04M
Goodwill$1.91M$1.91M$1.91M$1.91M$1.91M
Total assets$78.34M$19.43M$6.22M$20.94M$26.27M
Current liabilities$7.02M$9.51M$13.73M$15.52M$4.98M
Total liabilities$7.47M$9.97M$14.20M$16.09M$5.93M
Shareholders' equity$70.87M$9.46M-$7.98M$4.85M$20.35M
Shares outstanding153.10M73.98M32.13M21.01M15.90M
Cash flow statement
Operating cash flow-$28.39M-$35.40M-$31.41M-$23.81M-$26.02M
Investing cash flow—$0-$5.50M-$4.50M$0
Financing cash flow$86.30M$46.76M$22.32M$24.08M$12.07M
Stock-based compensation$1.96M$1.56M$2.09M$1.73M$1.01M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.